Urgent

CAR-T cell therapy - overview & toxicity

CAR-T · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chimeric antigen receptor T-cell therapy uses genetically engineered autologous T cells to target tumour antigens (e.g. CD19, BCMA) in refractory lymphoma, leukaemia and myeloma. Its hallmark toxicities are cytokine release syndrome and neurotoxicity, needing specialist recognition.

Red flags

  • High fever with hypotension/hypoxia (severe CRS)
  • Falling consciousness, seizures, dysphasia (severe ICANS)
  • Features of HLH/macrophage activation (very high ferritin, cytopenias)
  • Tumour lysis syndrome
  • Neutropenic sepsis

Assessment

Differential diagnosis

  • Cytokine release syndrome vs sepsis
  • ICANS vs CNS infection / metabolic encephalopathy
  • Tumour lysis syndrome
  • Macrophage activation / HLH
  • Infusion reaction

Investigations

  • Baseline and serial FBC, CRP, ferritin, fibrinogen (CRS/HLH markers)
  • Renal, liver function and tumour lysis labs
  • Neurological assessment with ICE score for ICANS
  • Blood cultures/septic screen (overlap with CRS)
  • Coagulation screen
  • Imaging/EEG/CSF for severe neurotoxicity

Management

  • Select eligible patients (refractory/relapsed CD19+ B-cell malignancies, BCMA+ myeloma) at an accredited centre
  • Harvest T cells by apheresis, manufacture the product, and bridge disease as needed
  • Give lymphodepleting chemotherapy before infusion
  • Admit for infusion with intensive monitoring for CRS and neurotoxicity
  • Grade and treat cytokine release syndrome: supportive care, tocilizumab for significant CRS, add corticosteroids if severe/refractory
  • Grade and treat ICANS primarily with corticosteroids (tocilizumab is less effective for neurotoxicity)
  • Give tumour lysis prophylaxis and manage cytopenias and hypogammaglobulinaemia
  • Provide antimicrobial prophylaxis and treat infections promptly (overlap with CRS)
  • Monitor for prolonged cytopenias, B-cell aplasia and rare delayed neurotoxicity
  • Arrange long-term follow-up for relapse and late effects

Drugs & doses

Tocilizumab 8 mg/kg IV (max 800 mg) for significant cytokine release syndrome, repeatable
Dexamethasone 10 mg IV (escalating) or methylprednisolone for severe CRS/ICANS
Lymphodepletion: fludarabine 30 mg/m2 + cyclophosphamide 300-500 mg/m2 IV for 3 days
Levetiracetam for seizure prophylaxis/treatment in ICANS; IVIg for hypogammaglobulinaemia

Disposition

Accredited CAR-T centre with inpatient monitoring; critical care for severe CRS/ICANS; structured long-term follow-up.

Complications & pitfalls

  • Cytokine release syndrome
  • Immune effector cell-associated neurotoxicity (ICANS)
  • Prolonged cytopenias
  • Hypogammaglobulinaemia and infections
  • B-cell aplasia
  • Relapse / antigen escape

Exam pearls

  • CRS is managed with tocilizumab and steroids; ICANS responds better to steroids than tocilizumab
  • CRS and sepsis look alike - treat for both until cultures clarify
  • The ICE score standardises neurotoxicity grading
  • Very high ferritin suggests overlapping HLH/macrophage activation
  • Only accredited centres with trained teams should deliver CAR-T

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.